Nigeria is not ready to take over local manufacture of essentials drugs needed in the country, according to a group of drugs manufacturers under the Pharmaceutical Society of Nigeria (PSN).
Nigeria’s restriction on the importation of essential medicines from non-ECOWAS countries signals a defining moment for its health sector, as experts say the move is strategic but warns of several implications.
As part of its 2026 fiscal policy shift, the government recently banned the importation of several commonly used drugs, including paracetamol, metronidazole, cotrimoxazole, penicillin, gentamicin, and chloroquine, among others from non-ECOWAS countries.
The policy aims to cut dependence on imports, conserve foreign exchange, and push local pharmaceutical companies to the forefront. But beneath that intent lies a fragile system now under pressure to deliver more with less external support.
“The ban is a strategic economic and health policy decision with multiple implications,” said Ibrahim Tanko, president of the Pharmaceutical Society of Nigeria (PSN).
“It protects local manufacturers, reduces pressure on foreign exchange, and strengthens medicine security by reducing reliance on long international supply chains. It also enhances regulatory oversight through agencies like the National Agency for Food and Drug Administration and Control (NAFDAC) and the Pharmacists Council of Nigeria (PCN),” Tanko added.
For years, Nigeria has relied heavily on imported medicines, with as much as 60 to 65 percent of drugs sourced from abroad, especially Active Pharmaceutical Ingredients (APIs).
That dependence has left the country exposed to global disruptions and currency volatility. The new policy attempts to reverse that trend, but it also shifts the burden of supply almost entirely to local manufacturers who are still navigating structural challenges.
“If we want an economy that is resilient, we must prioritise production over importation,” said Muda Yusuf, chief executive of Centre for the Promotion of Private Enterprise (CPPE).
Despite the optimism, experts warn that local production capacity is not fully optimised as infrastructure gaps persist, and raw materials are still largely imported.
Read Also: Nigeria’s fish production rises by 300,000MT in 2025 – Minister
Short-term strain, long-term promise
One of the major concerns raised by experts is that the ban could trigger short-term constraints such as drug shortages and price hikes for essential medicines like anti-malarials and paracetamol. The reason, they opine, is that supply chains do not adjust overnight, and manufacturers cannot instantly scale up to fill the gap left by imports.
“It is unrealistic to deny that this risk is real in the short term,” Tanko noted.
“We may see temporary shortages and price increases if demand outpaces local supply. However, if the rollout is phased, manufacturers are supported with incentives, and distribution improves under the National Drug Distribution Guidelines, these effects could be short-lived. Over time, prices may even stabilise,” he added.
Beyond supply concerns, the policy is also forcing a deeper reckoning within the industry. Nigeria has more than 120 registered pharmaceutical manufacturers and a strong base of technical expertise, yet longstanding issues continue to limit output.
Power supply remains unreliable, financing is difficult to access, and policy inconsistencies have slowed investment in local production, according to experts.
There are also risks tied to enforcement, as weak coordination could open the door to smuggling or counterfeit medicines, especially if scarcity begins to emerge. This places increased responsibility on regulators such as the Nigeria Customs Service and other health agencies to maintain control over the market.
“Local manufacturers can now price essential medicines more competitively against imports,” said Temitayo Akindele, corporate services manager at Fidson Healthcare Plc. “That ensures locally made, high-quality alternatives remain viable, but the transition must be carefully managed,” he added.
At its core, the policy reflects lessons from the COVID-19 pandemic, when global supply chains faltered and countries without local production capacity were left vulnerable. For Nigeria, this is a step toward health independence, but one that demands careful execution.
If backed with financing, infrastructure, and consistent policy support, the import restriction could reshape the pharmaceutical landscape and move the country closer to its goal of meeting 70 percent of its medicine needs locally. If not, it risks deepening existing gaps.
As the Pharmaceutical Society of Nigeria, through its president, clearly puts it, “This is not just a ban. It is a forced transition toward pharmaceutical self-reliance.”
